Insomniac Hedge Fund Guy
🧵 1/4 Savara Inc. ($SVRA) INSIDER BUY ALERT 💊
Director David Ramsay just placed a $416K bet on this rare disease biotech 🧬
Ramsay purchased 150,000 shares at $2.78 per share on March 31st, investing $416,250 in the clinical-stage biopharma company.
🔍 Our Analysis: Another lotto ticket in the biotech space. This is a horrific period for biotech stocks overall, with funding challenging and market sentiment deeply negative.
Ramsay's purchase is noteworthy as he brings significant biotech
Apr 14, 2025 at 4:27pmWeb
Show threadInsomniac Hedge Fund GuyApr 14, 2025
experience, having served on multiple boards including Mast Therapeutics, La Jolla Pharmaceutical (acquired in 2022), and currently Exuma Biotech. His willingness to deploy capital in this difficult environment suggests he sees potential in Savara's pipeline.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for autoimmune
Show threadInsomniac Hedge Fund GuyApr 14, 2025
pulmonary alveolar proteinosis, a rare lung condition with limited treatment options.
While early-stage biotech investments remain highly speculative, insider purchases in this challenging environment warrant attention, especially from directors with deep industry experience like Ramsay.
Are you finding selective opportunities in the beaten-down biotech sector, or staying clear until market sentiment improves? Do insider buys influence your decisions in this high-risk space? 🤔
Show threadInsomniac Hedge Fund GuyApr 14, 2025
➡️ Read our weekly analysis of insider buying here: https://bit.ly/3EmrLQA
#InsiderBuying #TheInsidersFund #SVRA #RareDiseases #NotInvestmentAdvice
Insider Buying Week 04-11-25 Every Bear Market Ends with a Tsunami of Insider Buying

What a great time to be an insider. Every bear market since 2001 has only ended with a plethora, a […]

The Insiders Fund